Skinvisible Inc (SKVI)

[NetworkNewsWire]

SKVI Advances Invisicare Delivery System

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) is targeting the pharmaceutical industry with its proprietary drug delivery system, Invisicare. Invisicare improves the delivery of ingredients to and through the skin. An article discussing this reads: “Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.”

To view the full article, visit http://nnw.fm/IlUp7

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com or www.Invisicare.com.